CI vs ELV
Cigna and Elevance Health, both Healthcare
Elevance Health is the larger company at $84B against $74B. On trailing earnings CI is the cheaper of the two at a P/E of 11.6 against 17.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year ELV returned +49% against +6.3% for CI. Ryufin's sector-relative Smart Score puts ELV ahead, 7/10 against 6/10.
| Figure | CI | ELV |
|---|---|---|
| Last close | $281 | $403 |
| Market cap | $74B | $84B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 11.6 | 17.8 |
| Dividend yield | 2.2% | n/a |
| 1-year return | +6.3% | +49% |
| 5-year return | +34% | +13% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cigna
Revenue of $72B in Q2 2026, net income $1.9B. Its largest reported line is Network Pharmacy, 49% of the disclosed total.
Elevance Health
Revenue of $50B in Q2 2026, net income $1.5B. Its largest reported line is Reportable, 89% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.